Valuation: Lakefront Biotherapeutics NV

Market Cap 1.62B 1.89B 1.52B 1.39B 2.6B 181B 2.64B 17.9B 6.98B 90.86B 7.1B 6.94B 301B P/E 2026 *
-13.2x
P/E 2027 * -6.66x
Enterprise Value -811M -947M -759M -695M -1.3B -90.6B -1.32B -8.97B -3.5B -45.51B -3.56B -3.48B -151B EV / Sales 2026 *
-8.55x
EV / Sales 2027 * -6.9x
Free-Float
74.64%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Lakefront Biotherapeutics NV

1 day-1.28%
1 week+1.82%
Current month+3.10%
1 month+0.41%
3 months+2.50%
6 months-16.78%
Current year-12.14%
1 week 23.64
Extreme 23.64
25.73
1 month 22.32
Extreme 22.32
25.73
Current year 22.32
Extreme 22.32
30.72
1 year 22.32
Extreme 22.32
32.74
3 years 20
Extreme 20
39
5 years 20
Extreme 20
66.28
10 years 20
Extreme 20
252.9
Manager TitleAgeSince
Chief Executive Officer 53 2025-05-11
Director of Finance/CFO 41 2025-07-06
Chief Operating Officer - 2026-05-31
Director TitleAgeSince
Director/Board Member 63 2019-10-21
Director/Board Member 49 2024-10-06
Director/Board Member 53 2025-05-11
Date Insider Type Main position Quantity % Market Cap.
1/28/26 Buy

Director

137 0.0002%
1/28/26 Buy

Director

375 0.0006%
1/28/26 Free

General Counsel

235,000 0.3566%
Change 5-day change 1-year change 3-year change Capi.($)
-1.28%+1.82%-10.09%-28.38% 1.89B
-0.62%+3.78%+2.62%+23.10% 51.61B
-1.07%+2.82%+465.96%+570.70% 44.89B
+1.47%+9.79%+35.92%+20.21% 42.77B
+1.44%+7.77%+19.38%+84.65% 42.58B
-0.93%-4.33%+16.18%+55.82% 31.82B
+1.32%+7.30%+33.89%+148.53% 17.33B
-0.60%+1.93% - - 16.63B
+0.36%+4.43%+9.53%+30.58% 14.76B
+1.28%+5.41%+82.40%+46.13% 14.09B
Average +0.14%+4.42%+72.86%+105.70% 27.84B
Weighted average by Cap. +0.17%+4.71%+98.57%+140.14%

Financials

2026 *2027 *
Net sales 94.87M 111M 88.76M 81.25M 152M 10.6B 155M 1.05B 409M 5.32B 416M 407M 17.61B 93.29M 109M 87.29M 79.9M 150M 10.42B 152M 1.03B 402M 5.23B 409M 400M 17.31B
Net income -40.7M -47.51M -38.08M -34.86M -65.41M -4.55B -66.28M -450M -175M -2.28B -178M -175M -7.55B -213M -248M -199M -182M -342M -23.76B -346M -2.35B -917M -11.93B -932M -912M -39.47B
Net Debt -2.43B -2.84B -2.27B -2.08B -3.91B -271B -3.96B -26.87B -10.48B -136B -10.65B -10.42B -451B -2.26B -2.64B -2.12B -1.94B -3.64B -253B -3.69B -25.02B -9.76B -127B -9.92B -9.71B -420B
Logo Lakefront Biotherapeutics NV
Lakefront Biotherapeutics NV (formerly Galapagos NV) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics NV prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas.
Employees
196
Date Price Change Volume
26-08-24 24.60 -1.28% 14,570
26-08-21 €24.92 +2.38% 68,233
26-08-20 €24.34 -4.55% 105,227
26-08-19 €25.50 +7.05% 176,325
26-08-18 €23.82 -1.41% 81,616
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
9
Last Close Price
24.92EUR
Average target price
30.28EUR
Spread / Average Target
+21.49%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LKFT Stock